Dendritic cell derived-exosomes: biology and clinical implementations.
Exosomes are nanometer-sized membrane vesicles invaginating from multivesicular bodies and secreted from different cell types. They represent an "in vitro" discovery, but vesicles with the hallmarks of exosomes are present in vivo in germinal centers and biological fluids. Their protein and lipid composition is unique and could account for their expanding functions such as eradication of obsolete proteins, antigen presentation, or "Trojan horses" for viruses or prions. The potential of dendritic cell-derived exosomes (Dex) as cell-free cancer vaccines is addressed in this review. Lessons learned from the pioneering clinical trials allowed reassessment of the priming capacities of Dex in preclinical models, optimizing clinical protocols, and delineating novel, biological features of Dex in cancer patients.
Chaput
Nathalie
N
ERM0208 Institut National de la Santé Et de la Recherche Médicale, Faculté de Médecine Paris Sud-Université, Paris XI, France.
Flament
Caroline
C
Viaud
Sophie
S
Taieb
Julien
J
Roux
Stephan
S
Spatz
Alain
A
André
Fabrice
F
LePecq
Jean-Bernard
JB
Boussac
Muriel
M
Garin
Jérôme
J
Amigorena
Sebastian
S
Théry
Clotilde
C
Zitvogel
Laurence
L
D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology* / Q000627:therapeutic use; D017321:Clinical Trials, Phase I as Topic; D003713:Dendritic Cells / Q000276:immunology / Q000378:metabolism; D011992:Endosomes / Q000737:chemistry / Q000276:immunology* / Q000378:metabolism; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology
D019496:Cancer Vaccines